The etiology of inflammatory bowel disease (IBD) is still not fully understood. Angiogenesis
is one of the crucial phenomena sustaining chronic inflammation in the gastrointestinal tract. It has been
also shown that the most potent anti-inflammatory drugs - anti-tumor necrosis factor alpha antibodies
down-regulate intestinal angiogenesis, what is believed to contribute to their therapeutic efficacy. There
are many proteins engaged in gastrointestinal angiogenesis, including pro-inflammatory cytokines, vascular
growth factors, and adhesion molecules. Several of them are considered to be promising molecular
targets for new drugs - monoclonal antibodies or fusion proteins. Here, we review new data highlighting the key role of proteins
that regulate immune-mediated angiogenesis in IBD, like vascular endothelial growth factor, hypoxia inducible factor,
angiopoietins, or basic fibroblast growth factor. We present the molecular mechanisms regulating the pathological proangiogenic
activity in inflammatory conditions in IBD. We also discuss how new anti-cytokine regimens affect the function
of angiogenesis-related proteins.
Keywords: Adhesion molecules, angiogenesis, angiopoietins, hypoxia inducible factor, inflammatory bowel disease, vascular
endothelial growth factor, vedolizumab.
Rights & PermissionsPrintExport